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OBJECTIVES This study was designed to assess the prevalence of major cardiovascular risk factors in familial
premature coronary artery disease (P-CAD), affecting two or more siblings within one
sibship.
BACKGROUND Premature CAD has a genetic component. It remains to be established whether familial
P-CAD is due to genes acting independently from major cardiovascular risk factors.
METHODS We recruited 213 P-CAD survivors from 103 sibships diagnosed before age 50 (men) or
55 (women) years old. Hypertension, hypercholesterolemia, obesity, and smoking were
documented at the time of the event in 163 patients (145 men and 18 women). Each patient
was compared with two individuals of the same age and gender, diagnosed with sporadic
(nonfamilial) P-CAD, and three individuals randomly sampled from the general population.
RESULTS Compared with the general population, patients with sporadic P-CAD had a higher
prevalence of hypertension (29% vs. 14%, p  0.001), hypercholesterolemia (54% vs. 33%, p
 0.001), obesity (20% vs. 13%, p  0.01), and smoking (76% vs. 39%, p  0.001). These
risk factors were equally or even more prevalent in patients with familial P-CAD (43% [p 
0.05 vs. sporadic P-CAD], 58% [p 0.07], 21% and 72%, respectively). Overall, only 7 (4%)
of 163 of patients with familial P-CAD and 22 (7%) of 326 of patients with sporadic P-CAD
had none of these conditions, as compared with 167 (34%) of 489 patients in the general
population.
CONCLUSIONS Classic, remediable risk factors are highly prevalent in patients with familial P-CAD.
Accordingly, a major contribution of genes acting in the absence of these risk factors is
unlikely. (J Am Coll Cardiol 2002;40:676–84) © 2002 by the American College of
Cardiology Foundation
Coronary artery disease (CAD) has a familial component
(1). Moreover, twin studies indicate that CAD is partly
genetic and that the genetic contribution to CAD is more
pronounced in premature forms of CAD (P-CAD) (2).
However, Mendelian-dominant atherogenic disorders, such
as familial hypercholesterolemia, account for only a small
fraction of P-CAD (5%) (3), indicating that the genetic
basis of P-CAD is, in most cases, complex. As such, the
molecular genetic basis of P-CAD remains to be elucidated.
Affected sibling-pair analyses are being increasingly used
to explore the genetic basis of complex diseases like P-CAD
(4). In this type of analysis, whole-genome scanning is
performed on large numbers of affected sibling pairs, and
genomic regions that are shared in excess between affected
siblings are subsequently screened for the presence of
specific sequence variants associated with the disease.
Whether causative genetic defects suffice to trigger the
development of familial forms of P-CAD independently
from classic risk factors, such as lipid disorders, hyperten-
sion and cigarette smoking, is a major issue that has
profound implications for predictive and preventive medi-
cine, as well as for research endeavors, and that has not been
fully documented yet.
A variety of convergent observations suggest that inde-
pendent genetic defects may be at work in familial forms of
P-CAD. A positive family history of P-CAD has been
repeatedly reported as an independent cardiovascular risk
factor (5,6). Next, atherosclerotic carotid plaques (7), de-
fects in myocardial perfusion (8), endothelial dysfunction
(9) and electrocardiographic abnormalities (10) have been
recently detected in apparently healthy first-degree relatives
of patients with P-CAD, and these associations have been
shown to persist after adjustment for classic cardiovascular
risk factors. In contrast, first-degree relatives of patients
with P-CAD have also been shown to present with an
From the *Department of Medicine and †Institute for Social and Preventive
Medicine, CHUV University Hospital, and ‡University Medical Policlinic, Lau-
sanne, Switzerland. This study was supported by the Swiss National Foundation for
Scientific Research (grant nos. 44471.95 and 32-61623.00 to Dr. Mooser and grant
nos. 3.856-0.83, 3.938.0.85, 32-9271.87 and 32-30110.90 to MONICA at Vaud/
Fribourg), Bern, Switzerland; the Octave Botnar and Placide Nicod Foundation,
Lausanne, Switzerland; MONICA at Canton de Vaud, Lausanne, Switzerland; and
Glaxo Smith Kline, Greenford, U.K. Dr. Mooser is presently affiliated with
GlaxoSmithKline in Greenford, UK.
Manuscript received July 10, 2001; revised manuscript received March 25, 2002,
accepted May 15, 2002.
Journal of the American College of Cardiology Vol. 40, No. 4, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)02017-X
elevated prevalence of metabolic abnormalities (11)—in
particular, hyperlipidemia (3,12), small, dense low-density
lipoprotein particles (13), and hypertension (14)—
suggesting that P-CAD in affected sibling pairs may be, at
least in part, mediated by a familial, possibly genetic
predisposition to these intermediate traits.
In the present study, we envisioned three scenarios to
account for the development of familial P-CAD. In the first
scenario, we reasoned that if familial P-CAD was due to
genetic defects acting independently from “traditional,”
major cardiovascular risk factors, one should observe a
prevalence of these risk factors in P-CAD–affected sibling
pairs lesser than or similar to the prevalence in the general
population and lesser than that in patients with sporadic
(i.e., nonfamilial) P-CAD, who may not carry such a
genetic predisposition. In the second scenario, P-CAD in
affected sibling pairs may be a consequence of genetic
defects leading to atherogenic metabolic disorders—the
paradigm here being familial hypercholesterolemia. If this
scenario is correct, one should observe a very high preva-
lence of metabolic disorders in P-CAD–affected sibling
pairs (even higher than that in patients with sporadic
P-CAD), a certain concordance for these intermediate traits
in P-CAD–affected siblings from the same sibship and a
prevalence of smoking equivalent to that in the general
population. Finally, in the third scenario, where P-CAD in
affected sibling pairs was due to a genetic predisposition to
metabolic disorders acting in concert with specific environ-
mental conditions like smoking, one would expect a preva-
lence of atherogenic metabolic disorders and smoking sim-
ilar to that in patients with familial and sporadic P-CAD
and higher than that in the general population.
To explore which of these scenarios is at work in familial
P-CAD, we examined the prevalence of hypertension,
hypercholesterolemia, obesity, and cigarette smoking in a
unique group of 213 P-CAD survivors from 103 Caucasian
sibships with two or more affected siblings, recruited in
Western Switzerland within the framework of the
GENECARD project, a multinational effort to elucidate
the genetic basis of CAD using an affected sibling-pair
approach. We compared these patients with familial
P-CAD with age- and gender-matched individuals ran-
domly sampled from the general population within the
framework of the Swiss MONICA project and with pa-
tients diagnosed locally with sporadic (nonfamilial)
P-CAD.
METHODS
Study design and recruitment of patients with familial
P-CAD. In the GENECARD project, which will be
described in detail separately (W.E. Krauss et al., manu-
script in preparation), P-CAD is defined by the presence of
acute myocardial infarction or angina with 50% stenosis
within a major coronary vessel on the angiogram, diagnosed
before age50 years for men and55 years for women. To
be included in the GENECARD study, P-CAD survivors
had to have at least one sibling who had equally survived
P-CAD. Cocaine users, patients with end-stage renal dis-
ease and individuals who had previously undergone radio-
therapy of the chest were excluded from the study.
To identify P-CAD–affected sibling pairs, we initially
screened the medical records of 35,000 patients who had
been admitted for heart disease between 1985 and 2000 to
our University Hospital and to four major public hospitals
and two large rehabilitation centers in Western Switzerland
(listed in the Appendix), covering a population of 1.2
million residents (Fig. 1). A total of 4,255 individuals
(100%) who had been diagnosed with P-CAD were iden-
tified. A letter describing the aim of the GENECARD
project was sent to 3,075 patients (72%); the remaining
1,180 patients (28%) were deceased or could not be located.
A total of 1,795 individuals (42%) responded to the letter
and provided a detailed history of CAD in their family. A
second letter was sent to responders who reported at least
one potentially eligible sibling; this letter asked for permis-
sion to contact the sibling. Potentially eligible siblings were
informed regarding the project and were asked for permis-
sion to examine their medical records. A total of 110
individuals (2.7%) with at least one sibling who had equally
survived P-CAD were identified after the presence of the
disease had been fully verified for all affected siblings in the
original documents. Seven individuals from separate sib-
ships refused to enter the study, so a total of 213 individuals
from 97 sibships with two P-CAD–affected siblings, five
sibships with three P-CAD–affected siblings, and one
sibship with four P-CAD–affected siblings were eventually
recruited. These individuals (all Caucasians) comprised the
familial P-CAD group. The procedures were in accordance
with institutional guidelines and the Swiss Office for Pa-
tients’ Protection. The protocol was approved by the local
ethics committees, and each participant provided written,
informed consent.
Major risk-factor profile at the time of the event.
Medical charts recorded at the time that the diagnosis of
P-CAD was initially made were retrieved for these 213
patients with familial P-CAD. A description of smoking
and hypertension and measurements of body mass index and
plasma total cholesterol levels (if measurement was per-
formed within 24 h of the initiation of symptoms or at least
after 12 weeks for subjects diagnosed with acute myocardial
infarction) were documented for 163 subjects diagnosed
before age 50 years (30 subjects for whom the complete
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
HDL  high-density lipoprotein
OR  odds ratio
P-CAD  premature coronary artery disease
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risk-factor profile was not properly documented and 20
women diagnosed between age 51 and 55 years were
excluded from this analysis), including 128 individuals from
64 sibships. In this analysis, hypertension was defined as
blood pressure 160/95 mm Hg or prescription of antihy-
pertensive agents; hypercholesterolemia as plasma total
cholesterol levels 6.5 mmol/l or prescription of lipid-
lowering agents; obesity as a body mass index 30 kg/m2;
and smoking as active cigarette smoking at the time of the
event or within the five preceding years. Plasma high-
density lipoprotein (HDL) cholesterol levels were only
available for 87 patients with familial P-CAD, and this
variable was not included in the analysis.
Identification of the sporadic P-CAD group. Patients
with familial P-CAD were compared with patients with
sporadic (nonfamilial) P-CAD. To identify these patients
with sporadic P-CAD, we selected, out of a group of 1,172
individuals who had been admitted to our University Hos-
pital for P-CAD and for whom a complete risk-factor
profile was recorded at the time of the event, 838 patients
who had responded to our letter. A total of 80 patients who
had no sibling and 115 patients who reported to have one or
more siblings affected with CAD (irrespective of age) were
excluded from the group, so that 643 patients with P-CAD
who had at least one sibling, but none reported to be
affected with CAD, were eventually included in the sporadic
P-CAD group (Fig. 1).
General population matching procedure and statistical
analysis. Each of the 163 patients with familial P-CAD
was randomly matched to two patients with sporadic
Figure 1. Strategy used to recruit premature coronary artery disease (P-CAD)–affected sibling pairs and to identify patients with sporadic P-CAD. A total
of 110 patients with familial P-CAD were originally identified, but 7 refused to enter the study, so that 103 probands with familial P-CAD and 110 affected
siblings were eventually recruited.
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P-CAD of the same gender and age. In addition, each
patient was randomly matched to three individuals of the
same gender and age, among 2,328 individuals aged 25 to
50 years who participated in two population-based health
examination surveys conducted in Western Switzerland
(Cantons of Vaud and Fribourg) in the periods 1988–1889
and 1992–1993 within the framework of the Swiss
MONICA project (15). An allowance for a small difference
in age (maximum of 3 years) was introduced in the match-
ing criteria to achieve a fixed case-control ratio of 1:2 (for
patients with sporadic P-CAD) or 1:3 (for individuals from
the general population). Conditional logistic regression for
case-control studies (16) was used to calculate the odds
ratios (ORs) and their confidence intervals (CIs) for the
various cardiovascular risk factors. Statistical analyses were
carried out using STATA (release 6.0, STATA Corp.,
College Station, Texas) and SPSS (release 4.0, SPSS, Inc.,
Chicago, Illinois).
RESULTS
We locally recruited 213 Caucasian P-CAD survivors (175
men and 38 women) from 103 sibships, with fully verified
P-CAD in the original documents (Fig. 1). Two sibships
(2%) fulfilled the clinical criteria for familial hypercholes-
terolemia (17). About half of the sibships for whom reliable
information was available (38 [48%] of 79) reported a
positive parental history of CAD, as defined by CAD in
either or both parents diagnosed before age 60 years for
fathers or 65 years for mothers; the remaining 24 families
Table 1. Clinical Characteristics of Patients With Familial P-CAD at the Time of the Event
and Their Matched Control Subjects
General Population
(n  489)
Sporadic P-CAD
Group (n  326)
Familial P-CAD
Group (n  163)
Gender (M/F) 435/54 290/36 145/18
Age (yrs) 44.0  4.6 44.0  4.5 44.0  4.6
Diagnosis of MI/angina — 195/131 82/81
TC (mmol/l) 6.4  1.3 6.4  1.5 6.5  1.5
Hypercholesterolemia (TC 6.5 mmol/l) 33% 54%* 58%*
HDL cholesterol (mmol/l) 1.27  0.35 1.09  0.50* 1.02  0.29*†
BMI (kg/m2) 26.0  3.6 26.9  3.9 27.2  3.9
Obesity (BMI 30 kg/m2) 13% 20%* 21%*
Hypertension 14% 29%* 43%*
Smoking 39% 76%* 72%*
Diabetes ‡ 7.7% 9.2%
*p  0.001 versus general population. †Plasma HDL cholesterol levels were available for 87 patients with familial P-CAD, and
a comparison was made with 174 age- and gender-matched patients with sporadic P-CAD and 261 age- and gender-matched
subjects from the general population. ‡The presence of diabetes was not recorded in the MONICA surveys, so these data are
missing. In the U.K. and other European countries, the prevalence of diabetes in Caucasians aged 50 years from the general
population appears to be 1.0%. Data are presented as the number or percentage of patients or the mean value  SD.
BMI  body mass index; HDL  high-density lipoprotein; MI  myocardial infarction; P-CAD  premature coronary
artery disease; TC  total cholesterol.
Figure 2. The prevalence of hypertension (HT), hypercholesterolemia (HC), obesity and cigarette smoking at the time of the event in 163 patients with
familial premature coronary artery disease (P-CAD) (solid bars), 326 age- and gender-matched patients with sporadic (nonfamilial) P-CAD (hatched bars)
and 489 age- and gender-matched individuals randomly sampled from the local general population (open bars). Hypertension was defined as blood pressure
160/95 mm Hg and/or prescription of antihypertensive agents; hypercholesterolemia corresponded to plasma total cholesterol levels 6.5 mmol/l and/or
prescription of lipid-lowering agents; obesity was defined as a body mass index 30 kg/m2; and smoking corresponded to active cigarette smoking at the
time of diagnosis or within the preceding five years. *p  0.05; **p  0.01; ***p  0.001.
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were not included in this analysis due to an unknown
condition or death from noncardiac origin of either or both
parents before age 60 years for men and 65 for women
years.
The major cardiovascular risk-factor profile (hyperten-
sion, hypercholesterolemia, obesity and smoking) at the
time of the event was documented for 163 P-CAD–affected
siblings (145 men and 18 women) diagnosed before age
50 years (Table 1), and the profile in these patients with
familial P-CAD was compared with that of 326 age- and
gender-matched patients with sporadic (nonfamilial)
P-CAD and 489 age- and gender-matched individuals
randomly sampled from the local general population (Fig.
1). The presence of diabetes was documented in patients
with familial P-CAD (9.2%) and in matched persons with
sporadic P-CAD (7.7%), but was not documented in the
MONICA participants, so this variable was not included in
the analysis. Plasma total cholesterol levels were similar in
the three groups; however, a higher proportion of individ-
uals receiving lipid-lowering agents was observed in the two
P-CAD groups compared with the general population (15%
and 9% vs. 2%). In contrast, plasma HDL cholesterol levels
were lower in both P-CAD groups than in the general
population (p  0.001). Overall, when compared with
patients with sporadic P-CAD, patients with familial
P-CAD presented with an equally elevated or even higher
prevalence of hypertension, hypercholesterolemia, combina-
tion of hypertension and hypercholesterolemia, obesity, and
smoking (Fig. 2). These risk factors were approximately
twice as prevalent in patients with sporadic P-CAD than in
the general population. Similar results were obtained when
comparing men with familial P-CAD with patients with
sporadic P-CAD sharing the same age and parental history
of CAD.
Next, we examined the intra-individual sum of major risk
factors within each group. Only a small fraction of patients
with familial or sporadic P-CAD (7 [4%] of 163 and 22
[7%] of 326, respectively) had none of these conditions, as
compared with 167 (34%) of 489 subjects in the general
population. On average, patients with familial P-CAD
presented with 1.9  0.9 risk factors, as compared with 1.8
 0.9 risk factors in patients with sporadic P-CAD (p 
0.06) and 1.0  0.9 risk factors in the general population
(p  0.001).
The prevalence of major risk factors varied according to
age (Fig. 3). Compared with the general population, the
prevalence of hypertension, hypercholesterolemia, obesity,
and smoking was higher in both P-CAD groups at all age
tertiles. No difference was observed between familial and
sporadic patients with P-CAD in the younger age tertile (27
to 42 years; n 53 and 106, respectively). In contrast, in the
third age tertile (47 to 50 years), patients with familial versus
sporadic P-CAD (n  56 and 112) had a higher prevalence
of hypertension (OR 3.1 [95% CI 1.6 to 6.2], p  0.001),
alone or in combination with hypercholesterolemia (OR 2.4
[95% CI 1.1 to 5.3], p  0.02), than did patients with
sporadic P-CAD. Overall, the sum of risk factors in this
third age tertile was higher in patients with familial versus
sporadic P-CAD (2.1  0.8 vs. 1.8  0.9, p  0.05).
The difference in the prevalence rate of hypertension and
hypercholesterolemia between patients with familial and
those with sporadic P-CAD was particularly pronounced
for the subset of patients with familial P-CAD with a
positive parental history of CAD (Table 2). Hypertension
was equally prevalent in the sporadic and familial P-CAD
groups when considering patients with familial P-CAD
with a negative parental history of CAD (35% vs. 31%, p 
Figure 3. The prevalence of risk factors in the general population (open
diamonds), in patients with sporadic premature coronary artery disease
(P-CAD) (solid triangles) and in patients with familial P-CAD (solid
circles), according to age tertiles. Groups and risk factors were defined as
described in the legend to Figure 2. *p  0.05 familial versus sporadic
P-CAD; ***p  0.001.
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NS). In contrast, the difference was very pronounced when
examining patients with familial P-CAD with a positive
versus negative parental history (53% vs. 29% and p 0.001
vs. p  0.05, respectively). This analysis suggested that
hypertension runs in these families and contributed to CAD
in both the parental generation and the sibling pairs
recruited here.
To further explore the familial aggregation of risk factors
in patients with familial P-CAD recruited here, we next
examined the intra-sibling-pair concordance for these risk
factors. The proportion of sibling pairs with both siblings
being hypertensive was significantly higher than the pro-
portion observed for their matched control subjects from the
sporadic P-CAD group (26% vs. 9%, OR 3.3, p  0.004)
and the general population (3%, OR 12.3, p  0.001).
Similarly, the concordance for hypercholesterolemia was
higher in familial P-CAD sibships than in the control
subjects from the general population (33% vs. 22%, OR 2.0,
p  0.03), but not for obesity or smoking. Similar conclu-
sions could be drawn when testing for concordance using
the Kappa test (Table 3). In this analysis, the observed
intra-sibling-pair concordance was higher than expected
when assuming independence from hypertension (62.5% vs.
50.2%, p  0.02) and hypercholesterolemia (62.5% vs.
49.7%, p 0.02) between siblings, but not for obesity or for
smoking. Finally, the high proportion of sibling pairs with
two hypertensive siblings was mostly accounted for by those
sibling pairs with a positive parental history of CAD (40%
[n  23] vs. 13% in sibling pairs with a negative parental
history [n  25], p  0.04).
Six sibships were characterized by the presence of three or
four P-CAD survivors, and these sibships are particularly
illustrative of the findings reported earlier (Fig. 4). Only one
of these six sibships (family no. 80) had a positive parental
history of CAD diagnosed before age 60 years (for fathers)
and 65 years (for mothers), and 9 of 12 parents survived into
their 60s (note that in family no. 75, the father died at age
83 years and the mother was aged 86 years). None of the
affected siblings had no risk factor, and all siblings had at least
one metabolic risk factor (hypertension, hypercholesterolemia,
or obesity and diabetes), except the younger sibling in family
Table 2. Prevalence Rates of Major Cardiovascular Risk Factors in Patients With Familial P-CAD and Their Respective Age- and
Gender-Matched Control Subjects, According to Parental History of CAD in Patients with Familial P-CAD*
Prevalence (%) OR (95% CI)
General
Population (A)
Sporadic P-CAD
Group (B)
Familial P-CAD
Group (C) B vs. A C vs. B C vs. A
Negative (n) 177 118 59
Positive (n) 192 128 64
HT
Negative 18% 31% 35% 2.0 (1.1–3.4) 1.3 (0.6–2.5) 2.5 (1.3–4.7)
Positive 11% 29% 53% 3.1 (1.8–5.6) 2.7 (1.4–5.2) 13.1 (5.4–31.6)
HC
Negative 33% 49% 54% 2.2 (1.4–3.7) 1.2 (0.7–2.3) 2.3 (1.3–4.1)
Positive 33% 66% 62% 3.3 (2.1–5.2) 0.9 (0.5–1.6) 3.2 (1.8–5.7)
HT  HC
Negative 5% 15% 24% 2.6 (1.2–5.6) 1.7 (0.8–3.7) 3.5 (1.6–7.8)
Positive 4% 17% 30% 3.4 (1.6–7.2) 1.9 (0.9–3.8) 8.3 (3.5–19.7)
Obesity
Negative 15% 18% 24% 1.3 (0.7–2.5) 1.4 (0.7–3.0) 2.0 (0.9–4.4)
Positive 10% 21% 14% 2.5 (1.3–4.8) 0.6 (0.3–1.4) 1.5 (0.6–3.5)
Smoking
Negative 40% 76% 73% 5.4 (3.0–9.2) 0.8 (0.4–1.7) 4.7 (2.3–9.5)
Positive 37% 77% 77% 5.8 (3.4–9.7) 1.0 (0.5–2.0) 5.4 (2.8–10.3)
*Family history of coronary artery disease was defined as positive if one or both parents had been diagnosed with coronary artery disease at age 60 years for men and 65 years
for women. This information was not available for 40 patients with familial P-CAD due to an unknown condition or death of noncardiac origin of the parent(s) before reaching
this age.
CI  confidence interval; HC  hypercholesterolemia; HT  hypertension; OR  odds ratio; P-CAD  premature coronary artery disease.
Table 3. Number of Siblings With Major Cardiovascular Risk
Factors in 64 Sibling Pairs* Affected With Familial Premature
Coronary Artery Disease
No. of Affected Siblings in
Sibling Pair
Kappa
Value0 1 2
HT
Observed 36 38 26 0.02
Expected† 30 50 20
HC
Observed 27 37 36 0.02
Expected† 20 50 30
HT  HC
Observed 59 32 9 0.09
Expected† 56 38 6
Obesity
Observed 57 38 5 0.64
Expected† 58 36 6
Smoking
Observed 9 39 52 0.30
Expected† 8 41 51
*Information was missing for 40 sibling pairs. †Value obtained when assuming
independence of risk-factor distribution among affected siblings from the same
sibship.
HC  hypercholesterolemia; HT  hypertension.
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no. 80 who was diagnosed with P-CAD at age 40 years. When
recruited at age 47 years, however, this person was obese and
hypercholesterolemic. Hypertension tended to aggregate in
siblings from four of six families (family nos. 39, 80, 96, and
108), whereas hypercholesterolemia affected at least two sib-
lings in five of six families (except family no. 39).
DISCUSSION
The major finding of this study is that familial P-CAD is
associated with a prevalence of hypertension, hypercholes-
terolemia, obesity, and cigarette smoking that was about
twice as high as that in the general population and equally
Figure 4. Aggregation of cardiovascular risk factors at the time of the event in six sibships with at least three siblings affected with premature coronary artery
disease (P-CAD). Males are represented by squares and females by circles. The numbers beneath the symbols refer to the age when the diagnosis of P-CAD
was made, whereas the age for the parents refers to the age at death (numbers in parentheses) or at the time that their P-CAD–affected siblings were recruited
(age at death of the father for family no. 39 was unknown). Solid upper left corner hypertension; solid lower left corner smoking; solid upper right corner
 hypercholesterolemia; and solid lower right corner obesity and/or diabetes, as defined in the legend to Figure 2. Arrows indicate probands. Plasma cholesterol
levels were missing for siblings 1 and 3 from family no. 53, sibling 1 from family no. 80 and sibling 1 from family no. 96, and the diagnosis of hypercholesterolemia
was based on values obtained when these individuals were recruited. The father in family no. 80 died of P-CAD at age 49 years.
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high, if not higher, than that in patients with sporadic
P-CAD. Moreover, hypertension and, to a lesser extent,
hypercholesterolemia were associated with a parental history
of CAD and tended to aggregate in sibling pairs recruited
here. Finally, cigarette smoking was the most prevalent risk
factor in both P-CAD groups. Taken together, these data
illustrate the importance of hypertension and dyslipidemia,
as well as life-style (particularly smoking), in the develop-
ment of both familial and sporadic P-CAD.
Comparison with other studies and limitations of the
present study. Only limited information is available on
cardiovascular risk factors in P-CAD (18–20). The present
study is based on a unique, ethnically and geographically
homogeneous, large group of sibling pairs for whom
P-CAD had been fully verified in the original documents
and who had been carefully matched to local patients with
sporadic P-CAD and individuals randomly sampled from
the general population during the same period. Neverthe-
less, this study has its limitations. The prevalence, at the
time of the event, of major risk factors in patients with
P-CAD was based on a retrospective analysis of medical
records. This approach was dictated by the extreme rarity of
sibships with multiple P-CAD survivors in Western Swit-
zerland (a region characterized by one of the lowest age-
adjusted incidences of CAD in industrialized countries)
(15,21) and the fact that a substantial proportion of partic-
ipants had changed their profile after being diagnosed with
P-CAD (for instance, 55% of those individuals who were
smokers when initially diagnosed with P-CAD had quit
smoking at the time they were recruited in the present
study). Next, only survivors were included in the familial
P-CAD group to be recruited into the GENECARD
project; if the factors under study are related to both the risk
of P-CAD and survival, this may introduce a confounding
factor in the assessment of cardiovascular risk. For example,
because diabetes both promotes the development of athero-
sclerosis and leads to a poorer outcome after myocardial
infarction, this risk factor may be under-represented in the
familial P-CAD group. Finally, a series of risk factors, such
as HDL cholesterol levels, lipoprotein(a) or homocystine-
mia, could not be examined in the present study.
Despite these limitations, our present results on sporadic
P-CAD are in very close agreement with autopsy studies on
premature atherosclerosis (19), as well as prospective studies
on P-CAD (18). In the Bogalusa Heart Study (19), the
extent of atherosclerosis in young adults, assessed at au-
topsy, closely correlated to the number of cardiovascular risk
factors, whereas in the Chicago Heart Association Detec-
tion Project in Industry Study (18), risk factors such as
cholesterol levels in plasma, systolic blood pressure and
cigarette smoking were highly predictive of death due to
CAD in men aged 18 to 39 years. Finally, our data are in
agreement with those of Williams et al. (20), who reported
an elevated prevalence of lipid disorders in 44 patients with
P-CAD from 33 families with two or more P-CAD–
affected siblings.
Clinical implications. The elevated prevalence of major
cardiovascular risk factors in patients with familial P-CAD
is associated with a series of immediate implications for
preventive medicine and genetic endeavors. From a clinical
standpoint, lipid disorders, hypertension, and smoking are
remediable risk factors. The absence of these conditions is
associated with a very low incidence of heart disease and a
longer life-expectancy in the general population (22), and
there is no reason to believe that members of families
heavily loaded with CAD will not benefit as much as the
general population from interventions aimed at reducing
these remediable risk factors. Given the familial aggregation
of lipid disorders and hypertension in first-degree relatives
of patients with P-CAD (11–13), the presence of these risk
factors should be sought and treated vigorously in unaffected
siblings and, possibly, in their offspring.
Implications for the genetics of CAD. The implications
of the present study for genetic endeavors on CAD are not
less important. The very high prevalence of smoking,
hypertension and hyperlipidemia raises the question as to
whether familial P-CAD in the patients recruited here is
somehow genetic. The data provide part of the answer to
this question. First, the elevated prevalence of hypertension
and hypercholesterolemia among patients with familial
P-CAD, the concordance for these traits in affected sibling
pairs, and the association of hypertension with a positive
parental history of CAD, all converge to support the
presence of a familial, possibly genetic predisposition to
these traits, which indirectly contributes to the development
of P-CAD, at least in a subset of sibships. Next, genes may
be at work in some patients to promote the development of
P-CAD in the presence of major risk factors. The presence
of such genes for CAD has recently been demonstrated for
a particular sequence variant within the lipoprotein lipase
gene (D9N), which exclusively increases the risk for heart
disease in smokers (23). Finally, the fact that patients with
familial P-CAD had a risk-factor profile worse than that of
patients with sporadic P-CAD in the third age tertile
renders a major contribution of genes acting independently
from well-known classic risk factors unlikely, at least in this
age category. Taken together, our present data reinforce the
need to more closely investigate the gene–environment
interactions in genetic studies on CAD and to further
explore the genetics of hypertension and hyperlipidemia.
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APPENDIX
Data were derived from the medical records of the following
institutions: CHUV University Hospital, Lausanne: Peter
Burckhardt (Department of Medicine), Lukas Kappen-
berger and Jean-Jacques Goy (Division of Cardiology),
Ludwig von Segesser (Department of Cardiovascular Sur-
gery) and Marie-Denise Schaller (Division of Intensive
Care Unit); Centre de Re´habilitation de Genolier: Ce´dric
Vuille; Centre de Re´habilitation de la Lignie`re: Claude-Alain
Nacht; Hoˆpital des Cadolles de Neuchaˆtel: Rehza Kehtari;
Hoˆpital Cantonal de Fribourg: Claude Regamey, Jean-
Christophe Stauffer, Adrien Nicole, and Benoıˆt Quarten-
oud; Hoˆpital du Sud du Canton de Fribourg a` Riaz: Jean-
Daniel Morard; and Hoˆpital de la Ville de Sion: Pierre Vogt
and Christophe Imsand.
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